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INTRODUCTION 24 25
Bronchopulmonary dysplasia (BPD) of premature infants is currently characterized by 26 continuing requirement for supplemental oxygen and/or respiratory support at 36 weeks post 27 menstrual age (PMA). BPD is the most common form of chronic lung disease in infants born 28 prematurely and is associated with long-term respiratory morbidity, neurodevelopmental 29 abnormalities, and death (35) . The pathogenesis of BPD includes lung immaturity, with reduced 30 pulmonary surfactant and low antioxidant and immune defenses, plus exposure to insults of 31 hyperoxia, barotrauma from ventilator support, and infections that damage lung epithelium and 32 elicit inflammation. Sequelae of this injury are arrested lung development, fibrosis and altered 33 airway reactivity (7, 19, 24, 33, 35, 38, 47) . 34
Therapeutic options for the prevention and treatment of BPD are limited and have not 35 substantially affected the incidence of disease (reviewed in (26, 28)). For example, vitamin A 36 treatment evokes a modest reduction of BPD but is not in general use, and caffeine reduces 37 oxygen use and is routinely used for prevention of apnea. Postnatal dexamethasone therapy 38 improves respiratory status acutely and decreases the incidence of BPD. However, longer 39 courses of this therapy are associated with neurodevelopmental abnormalities. Inhaled nitric 40 oxide (iNO) is used off-label in preterm infants to prevent BPD, however, the general efficacy of 41 the drug has been brought into question (20) . 42
The majority of studies evaluating the effectiveness of iNO have been performed in 43 individuals with predominantly European ancestry (6). However, in the entire cohort of the Trial 44 of Late Surfactant (TOLSURF) (60), and in a recent individual participant data meta-analysis 45 across selected iNO trials (5), the incidence of BPD was significantly lower following treatment 46
Study approval. 71
Patient recruitment for the TOLSURF study was approved by the Institutional Review Boards at 72 all participating sites including the University of California San Francisco. 73 74 Study Subjects. 75 TOLSURF was a masked, randomized, sham-controlled trial conducted in 25 US hospitals 76 (ClinicalTrials.gov: NCT01022580). The study was designed to assess the effect of late doses of 77 surfactant on BPD at 36 wk post menstrual age (PMA) in infants of 23-28 wk gestation who 78 required intubation and mechanical ventilation between 7 and 14 days of age (9). A total of 511 79 infants were enrolled, and all received iNO (Ikaria, Hampton, New Jersey) according to the 80 protocol followed in the NO CLD trial (10). BPD was assessed at 36 wk PMA by physiologic 81 testing as described (10). There was no statistical difference in BPD incidence between control 82 and surfactant-treated groups at 36 wk and the two groups were combined for this genetic study. 83 Some infants were co-enrolled in the multi-center, observational Prematurity and Respiratory 84
Outcomes Project (PROP) (52). 85
Genotyping and Quality Control. 86
DNA was extracted from tracheal aspirate cells from 454 infants whose parents consented for 87 DNA collection using cells from up to five tracheal aspirate collections per patient. DNA was 88 isolated using an AutoGeneprep 965 instrument (Autogen, Holliston, MA) by the manufacturer's 89 recommended standard protocol for human body fluids. In some cases, where protein 90 contamination was evident, DNA was re-precipitated using 3 volumes of 100% Ethanol and 3M 91 Ammonium acetate at a 3:1 ratio after incubation at -80 o C overnight. Samples were initially 92 quantified by Nanodrop (Thermofisher Scientific, Inc., Waltman MA) to access purity 93 (A260/280) followed by analysis using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA) 94 to more accurately access DNA quantity. The range of values for DNA concentration (ng/ul) 95 ranged from 10-1750, median 130; total DNA/patient (ng) 130-4200, median 1600; A260/280 96 1.32-1.91, median 1.77; 429 samples were of suitable quality and quantity for genotyping. 97
Genotyping was performed on the Affymetrix Axiom LAT1 array (WorldArray 4) that 98 contained >800,000 single nucleotide polymorphisms (SNPs) prior to quality control. SNPs were 99 filtered based on call rates < 95%, and Hardy-Weinberg equilibrium p-values <10 -6 using PLINK 100 (53). Subjects were evaluated for call rates, consistency between genetic and reported sex, 101 autosomal heterozygosity, and cryptic relatedness/genetic identity using IBD/IBS estimates in 102 collected for 4-8 hours, and NOx were assayed according to (50) and normalized to creatinine to 140 adjust for renal excretory function. NOx were measured at 3 different doses of iNO, including 2, 141 5, and 10-20 ppm. Genetic association testing at a single SNP was performed using linear 142 regression to test for a correlation between genotype and values of NOx at a dose of 5 143 ppm. Values of NOx at 5ppm were selected for analysis because they are highly correlated to 144 levels at 2 ppm, and more closely resemble a normal distribution as compared to 10-20 ppm. 145
For selected genes of interest, mRNA expression levels were obtained from a previous 146 study that performed RNAseq on 3 specimens of human fetal lung of 23 wk gestational age 147 (Gene Expression Omnibus, accession number GSE83888) (12 Individual proportions of genomic African ancestry were consistent with expectations 170 given maternal self-reported race/ethnicity ( Fig. 1, A Global African ancestry was not significantly different between infants with BPD/death 174 as compared to those surviving without BPD in Black/AA infants (beta=-0.015, se=0.37, p=0.97) 175 ( Fig. 1C ). However, African ancestry was protective for BPD/death in White Hispanic infants 176 (beta=-1.5, se=0.6, p=0.01) ( Fig. 1D ). Results were similar when all covariates were excluded. 177
African ancestry was further compared at individual loci in Black/AA infants using logistic 178 regression (i.e. local ancestry, or admixture mapping), and top associations were observed at 179 10q21 where African ancestry was protective for BPD/death (p=4.4x10 -4 , OR=0.17) and 18q21 180
where African ancestry was risky for BPD/death (p=2.7x10 -4 , OR=4.6) (Fig. 2) . The estimated 181 number of independent ancestry blocks was determined to be 478, and thus neither of the 182 admixture mapping peaks was statistically significant following Bonferroni correction 183 (alpha=1.0x10 -4 ). 184
Genome-Wide Association Study (GWAS) and Gene-based Comparisons. 186 187
Following genotype imputation, we tested the entire cohort for an association with 188 survival without BPD at 8.8 million individual variants, adjusting for global genetic ancestry, 189 gestational age, sex, birth weight, and multiple gestations. No individual variant was genome-190 wide significantly associated with BPD (all p-values > 5x10 -8 , Fig. 3 ). However, the top 191 association was observed at a variant within the intron of NBL1 (rs372271081, p=7.4x10 -7 ) ( Fig.  192 4A). The minor allele was protective for BPD (OR=0.17), and showed a similar effect within 193 each racial/ethnic group (Table 2 ). NBL1 and two additional genes within the same region 194 (CAPZB and MINOS1) were expressed in fetal lung at 23 wk gestation ( Fig. 4B ). Furthermore, 195 the minor allele at rs372271081 was significantly associated with decreased urinary NOx in 196 White infants, but was not significant in Black/AA or White Hispanic infants (Table 3 , Fig. 5A ). 197
Notably, the protective allele for BPD at rs372271081 is at a somewhat higher frequency in 198 populations with African ancestry (Fig. 5B ). 199
To increase statistical power, we combined the results of association testing of individual 200 variants within known genes to create a single gene-based statistic. No individual gene was 201 significantly associated with BPD following Bonferroni correction for 17,670 tests (the number 202 of genes tested, alpha=2.8x10 -6 ) ( Table 4 ). However, by restricting our comparisons to 21 203 candidate genes whose expression is dysregulated in BPD lungs, variation in CCL18 was 204 significantly associated with BPD (p=0.0011). This gene is expressed at a low level in 23-wk 205 human fetal lung (0.31±0.10 cpm). None of the genes implicated from Li et al. (40) were 206 significantly associated with BPD (minimum p=0.0018, ADCY8), nor were 11 NO-related 207 candidate genes (Table 5) with reported associations to human disease (minimum p=0.18, 208 KALRN). 209
Pathway Analysis. 211
Pathway analysis can be a powerful means to identify an enrichment of genes with 212 marginal signals of association on their own, but which function in a similar biological pathway. 213
Pathway analysis was performed using GREAT (45) on 1,024 genes with gene-based p-values < 214 0.05 as compared to 17,640 genes as a background. A total of five pathways/gene sets were 215 identified with a false discovery rate (FDR) < 0.05 from the Panther and MSigDB databases; this 216 group contains two pathways related to cancers, one related to immune function, one related to 217 methylation marks, and one implicated in experimental lung injury ( Table 6 ). The pathway of 218 highest statistical significance (p=5x10 -12 ) was "Genes within amplicon 1q21 identified in a copy 219 number alterations study of 191 breast tumor samples". Eight of the 11 genes in this pathway are 220 expressed in human fetal lung at 23 wk GA, and none are regulated by glucocorticoids, which 221 enhance fetal lung maturity. Biological functions of potential relevance to lung development, 222 injury, and repair for these genes include tyrosine kinase receptor signaling pathway (EFNA4, 223 RUSC1, SHC1, ADAM15), developmental processes (EFNA4, RUSC1, ZBTB7B, PBXIP1, 224 SHC1, ADAM15, PYGO2) including angiogenesis (SHC1), NF-kappaB signaling (RUSC1, 225 ZBTB7B), and sex steroid receptor signaling (PBXIP1, SHC1). 226 Pathway analysis using Ingenuity Pathway Analysis (IPA) of 181 genes with gene-based 227 p-values < 0.01 of 209 canonical pathways identified two with a significant enrichment of genes 228 following a Bonferroni correction: agranulocyte adhesion and diapedesis (p=3.06x10 -5 ) and 229 granulocyte adhesion and diapedesis (p=1.22x10 -4 ); genes in these two pathways are identical 230 except for MYL9 (Table 7) . With the exception of CLDN17, all genes identified in these 231 pathways are expressed in human fetal lung (12). All infants in TOLSURF were <28 wk gestation and were intubated at 7-14 days, representing 239 infants with severe early respiratory failure and high risk for BPD as reflected by the occurrence 240 of BPD/death in 68.5% of the total population (9). In addition, infants were enrolled from 25 241 different U.S. sites, providing both racial/ethnic and geographic diversity. The diagnosis of BPD 242 was assigned on a physiologic basis using an oxygen/flow reduction challenge to establish a 243 requirement for respiratory support. Thus, it is possible that some of our findings may be 244 restricted to extremely premature infants with severe early respiratory disease. Other unique 245 characteristics of our cohort are exposure to late surfactant treatment in approximately half of the 246 infants, and the use of iNO for 3 wk in all infants. Although surfactant therapy transiently 247 improved respiratory status it did not affect outcome at 36 wk PMA. iNO therapy likely 248 influenced outcome in African American infants, but not Caucasians, and thus we examined NO 249 metabolism as it relates to genetic associations with BPD in our study. 250
Higher genomic levels of African ancestry were associated with better respiratory 251 outcome in iNO-treated infants with maternal self-reported Hispanic White race/ethnicity but not 252 for infants with maternal self-reported Black/African American race/ethnicity. While the 253 protective effect of African genomic ancestry in White Hispanic infants requires independent 254 replication, our results suggest that a protective effect of African ancestry may be saturated at 255 lower levels of ancestry than is present in the majority of Black/African American infants in the 256 study, or may reflect the presence of differential gene-environment interactions. Specifically, in 257
White Hispanic infants, the proportion of African ancestry ranged from 1.2-63% (median of 258 6.3%) as compared to 40-100% (median of 85%) in Black/African American infants. 259
Genetic ancestry does not form a direct causal relationship, but rather indicates 260 differences in the underlying patterns of genetic variation in infants with/without BPD that differ 261 by continental origin. If only small proportions of African ancestry are required for a protective 262 effect, this would suggest a highly polygenic contribution to BPD distributed throughout the 263 genome. Admixture mapping in Black/AA infants identified two suggestive, but not statistically 264 significant peaks, at 10q22 and 18q21, whereby African ancestry was associated with both a 265 decreased and increased risk of death/BPD, respectively. Therefore, admixture mapping further 266 supports the hypothesis that the effect of ancestry is not limited to a single locus of large effect. 267
It is possible the relationship between ancestry and BPD is restricted to infants receiving iNO, 268
given that the incidence of BPD in many studies doesn't vary between racial/ethnic groups in 269 untreated infants (13); furthermore, prior studies have identified racial differences in endogenous 270 NO levels or metabolism in infants (8) and adults (34, 36, 37, 44). 271
In our agnostic scan including ~9 million genotyped and imputed variants, no individual 272 variant was genome-wide significantly associated with survival without BPD. This was not 273 unexpected given our small sample size, and is consistent with prior GWAS that similarly failed 274 to identify individual variants with large effects (4, 29, 61). Modest sample size is a limitation 275 common to genetic studies of preterm infants, and thus there is a need to integrate additional 276 significantly associated with differences in NOx in White infants, whereby the protective allele 278 for BPD was associated with decreased levels of NOx in the urine following treatment of iNO. 279
However, we found no significant association between genotype and NO metabolites in We further performed hypothesis-driven tests of association with BPD using a set of 21 308
genes that are dysregulated in BPD lungs (15), and 11 genes in the nitric oxide pathway that are 309 reported to have variants associated with disease (Table 5) . First, we hypothesized that genes 310 showing differential expression in BPD-dysregulated vs. control lungs may contain variants that 311 contribute to survival without BPD. We found a significant association with genetic variation in 312 a single gene -CCL18, a cytokine involved in the immune response that promotes collagen 313 production in lung fibroblasts (43) and is associated with pulmonary fibrosis and interstitial lung 314 diseases in adults (51, 66). Inflammation is known to be important in the pathogenesis of BPD, 315 and anti-inflammatory therapy (dexamethasone) suppresses a variety of inflammatory mediators, 316 including CCL18, and reduces BPD (12, 26). Second, because all infants in the study received 317 iNO, we hypothesized that variation in genes in the NO pathway may contribute to differential 318 response to iNO treatment as indicated by survival without BPD. Yet, no individual variant or 319 candidate gene (based on known association with human disease) was significantly associated 320 with survival without BPD following correction for multiple tests. 321 exclusively observed in infants treated with iNO (5, 60), we hypothesized that genetic variants 323 that contribute to BPD may act through differential response to iNO. In support of this, the 324 protective allele for BPD at rs372271081 is significantly associated with decreased NOx and is 325 more common in populations with African ancestry. Several studies indicate reduced 326 bioavailability of NO in African Americans vs Caucasians, likely in part due to increased 327 oxidation of NO. In laboratory studies, release of NO from umbilical venous endothelial cells 328 was substantially lower in African American vs Caucasian infants (36, 44). Levels of urinary 329
NOx are lower in African American and Hispanic premature infants vs Caucasian infants 330 regardless of iNO treatment, reflecting baseline differences in NO metabolism and thus 331 bioavailability (8). In adults, African Americans are known to have increased frequency of 332 hypertension and cardiovascular disease, and a NO-targeted medication (isosorbide dinitrates 333 and hydralazine) is indicated therapy for heart failure specifically in African Americans (i.e., a 334 racially directed therapy) (34, 37). However, further studies are needed to evaluate the 335 contribution of rs372271081 to racial/ethnic differences in NO bioavailability and differential 336 response to iNO. 337 Pathway analyses identified pathways and sets of genes that were significantly enriched 338 for genes with association p-values < 0.05. Across IPA, Panther, and MSigDB datasets, a 339 common theme that emerged was genes involved in immune function, including granulocyte and 340 agranulocyte adhesion and diapedesis from IPA canonical pathways, toll receptor signaling 341 pathway from Panther, and genes upregulated in response to LPS exposure and mechanical 342 ventilation from MSigDB. These results suggest that variation in immune response, including 343 recruitment of leukocytes and lymphocytes, contributes to survival without BPD. 344
African ancestry is protective for BPD, and that an intronic variant in NBL1 may contribute to 346 BPD via differential activity of the TGF-b/BMP pathway and production/metabolism of NO. 347 Furthermore, we implicated variation in genes involved in the immune response, including 348 CCL18, as contributing to differences in respiratory outcomes of preterm infants. Table 1 .
Baseline characteristics of participants from the TOLSURF study included in the GWAS. P-values represent comparisons using a student's t-test for continuous measurements (gestational age, birth weight, and RSS at entry), and a chi-square test for categorical (% male, % multiple gestation). Demographics are shown by maternal self-reported racial/ethnic group; data are mean plus standard deviation in parentheses. RSS=respiratory severity score.
Non-Hispanic White:
African American: Hispanic White: Genes with low-CpG-density promoters bearing H3K4me3 marks in embryonic fibroblasts 4.1x10 -7 6.8x10 -4 2.5 35
BPD/ Death
Nearest neighbors of TAL1, based on the close agreement of their expression profiles with that of TAL1 in pediatric T cell acute lymphoblastic leukemia 6.7x10 -6 0.0076 5.0 11
Genes up-regulated in lung tissue upon LPS aspiration with mechanical ventilation 2.4x10 -5 0.020 2.2 32 Table 7 .
Canonical pathways from Ingenuity Pathway Analysis (IPA) with a significant enrichment of genes with association p<0.01 for survival without BPD. Statistical significance was determined using a Bonferroni adjustment for 209 canonical pathways tested (alpha=2.39x10 -4 ). 
Canonical Pathway

